SynthesisEuropean heart journal. Cardiovascular pharmacotherapy2021
Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials.
Synthesis in European heart journal. Cardiovascular pharmacotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Omega-3 Supplementation in Coronary Artery Bypass Graft Patients: Impact on ICU Stay and Hospital Stay-A Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- Impact of α-Linolenic Acid, the Vegetable ω-3 Fatty Acid, on Cardiovascular Disease and Cognition.Advances in nutrition (Bethesda, Md.) · 2022Pooled it
- A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events.The American journal of clinical nutrition · 2025Trial
- Review
- Cardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.Journal of cardiovascular development and disease · 2026Review
- Circulating fatty acid profiles and risk of pulmonary arterial hypertension: Evidence from a large prospective cohort study.Medicine · 2026Article
- Metabolic and Inflammatory Mechanisms Driving Atrial Fibrillation.Annual review of pharmacology and toxicology · 2026Review
- [Food supplements and fortified foods: benefits, risks and approaches to consumer protection].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Article
- [Nutritional therapy in ophthalmology-patients' interest and motivation].Die Ophthalmologie · 2025Article
- Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues.ESC heart failure · 2025Review
- Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints.Clinical drug investigation · 2025Article
- Inflammation pathways as therapeutic targets in angiotensin II induced atrial fibrillation.Frontiers in pharmacology · 2025Review
- Dietary Interventions in Heart Failure With Preserved Ejection Fraction: A Scoping Review.JACC. Advances · 2025Review
- Regulatory Compliance of Health Claims on Omega-3 Fatty Acid Food Supplements.Foods (Basel, Switzerland) · 2024Article
- Omega-3 Fatty Acids and Muscle Strength-Current State of Knowledge and Future Perspectives.Nutrients · 2024Review
- Inverse relationship between LDL-C/HDL-C ratio and atrial fibrillation in chronic kidney disease patients.Scientific reports · 2024Article
- Association Between Remnant Cholesterol and Risk of Incident Atrial Fibrillation: Population-Based Evidence From a Large-Scale Prospective Cohort Study.Journal of the American Heart Association · 2024Article
- Liver X Receptor Agonist 4β-Hydroxycholesterol as a Prognostic Factor in Coronary Artery Disease.Journal of the American Heart Association · 2024Observational
- Current Evidence and Future Directions of Omega-3 Supplementation and Cardiovascular Disease Risk.The International journal of angiology : official publication of the International College of Angiology, Inc · 2024Review
- Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial Fibrillation.Endocrine, metabolic & immune disorders drug targets · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.